“The initiation of this study is another important milestone for our Hsp90 inhibitor program,” said David Grayzel, M.D., vice president, clinical development and medical affairs, Infinity. “We are encouraged by the evidence of biological activity we saw in the Phase 1 portion of the study and are eager to further evaluate IPI-504 in Phase 2. Non-small cell lung cancer is an aggressive disease and we are grateful to the patients, their families, and the outstanding caregivers collaborating with us in order to develop potential new treatment options.”